04/16/2026
In December 2025, the FDA approved the first oral glucagon-like peptide-1 (GLP-1) weight-loss medication, ushering in a new phase in treatment for diabetes and obesity. Here are 5 things to know about the oral GLP-1 era.
Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.